Catalog No.
PHJ98001
Species reactivity
Human, Mouse, Rat
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant Human SCG3 (Phe20-Leu468).
Tested applications
ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000
Target
SgIII, Secretogranin-3, SCG3, Secretogranin III
Purification
Purified by antigen affinity column.
Accession
Q8WXD2
Applications
ELISA, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Suppression of matrigel-induced choroidal neovascularization by AAV delivery of a novel anti-Scg3 antibody., PMID:39333408
Optimal Humanized Scg3-Neutralizing Antibodies for Anti-Angiogenic Therapy of Diabetic Retinopathy., PMID:39273454
Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease., PMID:38589621
Anti-Scg3 Gene Therapy to Treat Choroidal Neovascularization in Mice., PMID:37509549
Secretogranin III Selectively Promotes Vascular Leakage in the Deep Vascular Plexus of Diabetic Retinopathy., PMID:37445707
Inhibitory effect of anti-Scg3 on corneal neovascularization: a preliminary study., PMID:36443679
Safety and Efficacy of Systemic Anti-Scg3 Therapy to Treat Oxygen-Induced Retinopathy., PMID:35468689
Comparative ligandomics implicates secretogranin III as a disease-restricted angiogenic factor in laser-induced choroidal neovascularization., PMID:35038348
Optimal Efficacy and Safety of Humanized Anti-Scg3 Antibody to Alleviate Oxygen-Induced Retinopathy., PMID:35008775
Secretogranin III stringently regulates pathological but not physiological angiogenesis in oxygen-induced retinopathy., PMID:35006382
Selectively targeting disease-restricted secretogranin III to alleviate choroidal neovascularization., PMID:34918375
Novel Insight in Idiopathic Normal Pressure Hydrocephalus (iNPH) Biomarker Discovery in CSF., PMID:34360799
TRPV1, TRPA1, and TRPM8 are expressed in axon terminals in the cornea: TRPV1 axons contain CGRP and secretogranin II; TRPA1 axons contain secretogranin 3., PMID:32863706
TRPV1, TRPA1, and TRPM8 are expressed in axon terminals in the cornea: TRPV1 axons contain CGRP and secretogranin II; TRPA1 axons contain secretogranin 3., PMID:38860239
Anti-secretogranin III therapy of oxygen-induced retinopathy with optimal safety., PMID:30644010
Secretogranin III as a novel target for the therapy of choroidal neovascularization., PMID:30633921
Secretogranin III promotes angiogenesis through MEK/ERK signaling pathway., PMID:29154827
Secretogranin III: a diabetic retinopathy-selective angiogenic factor., PMID:28856381
Secretogranin III as a disease-associated ligand for antiangiogenic therapy of diabetic retinopathy., PMID:28330905
Cetuximab plus radiotherapy for the treatment of locally advanced squamous cell carcinoma of the head and neck., PMID:19567214
For research use only. Not for human or drug use.
